Home
  • Our Company
    • Biopharmaceutical Acceleration Model®
    • Dynamic Assembly®
    • Kinetic™
    • Syneos One®
    • The Trusted Process®
    • Our Leadership
    • Our Vision, Mission and Values
    • Resource Library
    • Events
    • Awards
    • Site Relationships
    • Our Office Locations
  • Solutions
    • Clinical Development
      • Full Service
        • Decentralized Solutions
        • Bioanalytical Solutions
        • Early Phase
        • Phase II - III
        • Phase IIIb - IV
        • Real World and Late Phase
        • Medical Device and Diagnostics
      • FSP 360
        • Biostatistics and Statistical Programming
        • Clinical Data Management
        • Clinical Development Services Project Management
        • Clinical Monitoring
        • Drug Safety and Pharmacovigilance
        • Investigator Management Solutions
        • Medical Writing and Communications
        • Rater Training
        • Site Start Up
        • Site and Patient Access
        • Trial Master File Operations
    • Commercialization
      • Advertising
      • AnswerSuite
      • Behavioral Insights
      • Brand Commercialization
      • Brand Naming and Development
      • Clinical Field Teams
      • Commercial Model of the Future
      • Commercial Recruiting Solutions
      • Communications
      • Deployment Solutions
      • Digital and Social Media
      • Full-Service Commercial
      • Health Economics and Outcomes Research
      • Medical Affairs Transformation
      • Medical Communications
      • Policy and Advocacy
      • Portfolio Strategy
      • Public Relations
      • REMS and Risk Management (PMO)
      • Reputation and Risk Management
      • Selling Solutions
      • Training and Learning Solutions
      • Value and Access
    • Consulting
      • Commercial Advisory Group
        • Portfolio Strategy and Transactions
        • Health Economics and Outcomes Research
        • Product and Franchise Strategy
        • Value and Access
        • Customer and Digital Engagement
      • Scientific and Medical Affairs Advisory Group
        • Medical Affairs
        • Quality and Compliance
        • Regulatory
      • Risk and Program Management Advisory Group
        • REMS and Risk Management (PMO)
      • R&D Advisory Group
        • Research and Development
    • Syneos One®
  • Therapeutic Expertise
    • Therapeutic Areas
      • Cardiovascular
      • Central Nervous System
        • CNS Analgesia
        • CNS Clinical Surveillance Team
        • CNS Neurology
        • CNS Psychiatry
      • Endocrine and Metabolic
      • Gastroenterology
      • Immunology and Inflammation
      • Infectious Disease and Vaccines
      • Ophthalmology
      • Respiratory
      • Women's Health
      • Oncology and Hematology
        • Targeted Therapies
        • Novel and Emerging Therapies
        • Immuno-Oncology
    • Cross-Functional Solutions
      • Biosimilars
      • Cell and Gene Therapy
      • Patient Voice
      • Pediatrics
      • Rare Diseases
    • Our Experience Hub
  • Insights Hub
  • Careers
  • インサイト ハブ
  • 中途採用
  • 新卒採用 (日本)
  • News
    • In The News
    • Press Releases
    • Press Kit
  • Investors
  • Investigators
  • Transparency
  • Suppliers
    • Supplier Code of Conduct
    • Standard Contractual Clauses for Suppliers
    • Supplier Diversity and Inclusion
    • Supplier Terms and Conditions
  • Contact
  • English
  • Français Canadien
  • 日本語

Search form

Home Insights Hub The 2021 Health Trends Series Acute Uncertainty
Trends

Acute Uncertainty

March 11, 2021
Content 

Pricing reform remains a looming challenge in the industry as governments around the world propose new approaches to limiting reimbursement and requiring new evidence against cost-effectiveness of care. Although much reform has been temporarily stalled due to more pressing pandemic issues, the outline is clear: rebates, discounting, and frameworks for more regional and aggressive tendering. Overall, total global spending is expected to continue to grow over the next several years, but at a slower rate — both due to pricing reform and competition among the significant numbers of new drugs coming to market.

Image or Video 

2021 Health Trends - Acute Uncertainty.png

2021 Health Trends - Acute Uncertainty
Critical Questions

What new evidence do we need to continuously demonstrate value?

What actions should we be taking to show our commitment to value and fair pricing?

Did you know...

Columns 
Content 
Image or Video 

Acute Uncertainty - Repricing.png

Acute Uncertainty - Repricing

Repricing: Japan’s 2018 overhaul of the Price Maintenance Premium (PMP) system narrowed the definition of what drugs were considered innovative and worthy of price premiums and exclusivity — creating a 32% drop in the number of drugs meeting the criteria. In 2021, the next wave of the reform will set in, requiring mandatory repricing of drugs annually.

— Pharma Manufacturing, 2020

Content 
Image or Video 

Acute Uncertainty - $35.png

Acute Uncertainty - $35

$35: In the U.S., manufacturers have teamed up with Medicare plans to create a moment of advocacy around pricing. They’ve developed a $35 capped co-pay program for insulin, to both help people struggling with the financial impacts of COVID-19 and to ensure they don’t try to ration their insulin. Eli Lilly was an early mover with a similar standalone Insulin Value Program which offers the $35 cap to people with commercial insurance or no insurance.

— Medscape, 2020;
— Stat News, 2020

 

Download a PDF of This Content Below.

The 2021 Health Trends Series
Retention Reboot
Privacy and Convenience
Enabled 
Download
Previous Next

Fill out the form below to download your requested Insights Hub Article.

*Required fields

By submitting this form, you agree to our Terms & Conditions and Privacy Policy of our website. You can withdraw your consent at any time. If you have any questions, please Contact Us.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Chapters

Chapter:
13
Privacy and Convenience
Chapter:
14
Retention Reboot
Chapter:
15
Acute Uncertainty
Chapter:
16
Combating Complexity
Chapter:
17
China: The New Pace Car of Change
Chapter:
18
Forming the Future Field

Pages

  • « first
  • ‹ previous
  • 1
  • 2
  • 3
  • 4
  • next ›
  • last »
Branded Logo
Subscribe to Our Newsletter Share

Related Content

The 2021 Health Trends Series
July 1, 2021
Retention Reboot
March 4, 2021
Privacy and Convenience
February 25, 2021
Interested in Syneos Health?
Get In Touch
Connect
  • LinkedInLinkedIn
  • TwitterTwitter
  • FacebookFacebook
  • InstagramInstagram

Syneos Health

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success. We lead with a product development mindset, strategically blending clinical development, medical affairs and commercial capabilities to address modern market realities. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. We support a diverse, equitable and inclusive culture. Contact Us

Our Headquarters
Corporate Headquarters
  • 1030 Sync Street
  • Morrisville, NC 27560
  •  
  • Phone: +1 919 876 9300
  • Fax: +1 919 876 9360
  • Toll-Free: +1 866 462 7373
Menu
  • Solutions
  • Therapeutic Expertise
  • Brand Directory
  • 労働者派遣法に基づく情報公開
  • Careers
  • Study Participants
  • Media
  • Business Ethics Helpline
  • Events
  • Transparency
© 2022 Syneos Health. All Rights Reserved.
  • Terms Of Use
  • Privacy Notice
  • Privacy Shield
  • Online Tracking Opt-Out